<DOC>
	<DOCNO>NCT00293488</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , SL-11047 , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase I trial study side effect best dose SL-11047 treating patient relapse refractory lymphoma .</brief_summary>
	<brief_title>SL-11047 Treating Patients With Relapsed Refractory Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) SL-11047 patient relapse refractory lymphoma . - Describe quantify toxicity SL-11047 administer patient relapsed refractory lymphoma . Secondary - Describe pharmacokinetics SL-11047 administer 30-minute IV infusion . - Assess response rate duration response patient treat SL-11047 . - Assess level SL-11047 within tumor tissue follow intravenous administration drug . - Determine sensitivity abnormal circulating macrophage SL-11047 . OUTLINE : This open-label , nonrandomized , dose-escalation study . Patients receive SL-11047 IV 30 minute day 1-5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SL-11047 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>N ( 1 ) , N ( 11 ) -diethylnorspermine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically* confirm Hodgkin 's nonHodgkin 's lymphoma ( NHL ) histology The following NHL type eligible : Diffuse large Bcell lymphoma Follicular lymphoma Mantle Cell lymphoma Marginal zone lymphoma ( include lymphoma mucosaassociated tissue [ MALT ] ) Anaplastic large cell lymphoma Peripheral Tcell lymphoma Cutaneous Tcell lymphoma T/NK cell lymphoma Angioimmunoblastic lymphadenopathytype Tcell lymphoma Burkitt 's lymphoma NOTE : * If histologic confirmation make initial diagnosis , confirmation relapse refractory disease make repeat histologic evaluation OR evidence regrowth site disease previously histologically confirm Relapsed refractory ≥ 2 prior therapeutic regimen OR patient ineligible receive potentially curative therapy Bidimensionally measurable evaluable ( e.g. , bone marrow infiltrative organ involvement ) disease physical exam radiographic study No suspicion evidence lymphomatous meningitis PATIENT CHARACTERISTICS : Life expectancy ≥ 12 week ECOG performance status 04 Not pregnant Negative pregnancy test Fertile patient must use medically prescribed contraception Absolute neutrophil count ≥ 1,000/mm^3* Platelet count ≥ 50,000/mm^3* Hemoglobin ≥ 8 g/dL* Serum creatinine ≤ 2.0 mg/dL Total bilirubin ≤ 2.0 mg/dL** Transaminases &lt; 5 time upper limit normal** No malignancy within past 5 year curatively treat nonmetastatic skin cancer situ cervical carcinoma No history significant symptomatic cardiac arrhythmia No history myocardial infarction No significant ventricular conduction abnormality ECG Holter monitoring , evidence following : Prior myocardial infarction Three premature ventricular contraction row No history pancreatitis No history recent gastrointestinal bleeding Must hemenegative stool enrollment NOTE : *Cytopenias due direct lymphomatous involvement allow NOTE : **Elevated due direct lymphomatous involvement allow PRIOR CONCURRENT THERAPY : See Disease Characteristics More 3 week since prior chemotherapy Recovered prior chemotherapy ( alopecia anemia allow ) More 3 week since prior investigational drug No prophylactic antiemetic course 1 No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>